Literature DB >> 27499239

The diagnostic utility of line probe assays for multidrug-resistant tuberculosis.

Marilyn M Ninan1, Mahasampath Gowri2, D J Christopher3, Priscilla Rupali4, Joy S Michael1.   

Abstract

Owing to the burden of multidrug-resistant tuberculosis, molecular techniques have been approved by the WHO for the rapid diagnosis of the same. The objectives of this prospective, diagnostic study, conducted at Christian Medical College, a tertiary care center in South India, were to compare the performance of line probe assay (GenoTypeMTBDRplus) with culture, as well as the Xpert MTB/Rif assay on sputum samples. Ninety-one consecutive suspects of multidrug-resistant pulmonary tuberculosis patients from January 2013 to June 2013 were enrolled in this study and the results of line probe assay compared to culture and Xpert MTB/Rif. Compared to culture, the assay demonstrated a sensitivity and specificity of 81.5% (95%CI 67.4-91.1%) and 87.5% (95%CI 71-96.5%) for the detection of tuberculosis, with sensitivity and specificity of 100% (95%CI 85.2-100%) and 93.8% (95%CI 69.8-99.8%), respectively, for rifampicin resistance. For isoniazid resistance, sensitivity and specificity were 89.3% (95%CI 71.8-97.7%) and 100% (95%CI 71.5-100%), respectively. Compared to Xpert MTB/Rif assay, the assay showed a sensitivity of 80% (95%CI 68.2-88.9%) and specificity of 100% (95%CI 85.8-100%) for the detection of tuberculosis a sensitivity of 94.3% (95%CI 80.8-99.3%) and specificity of 94.1% (95%CI 71.3-99.9%) for rifampicin resistance was attained. This assay performed well on smear positive samples, but poorly on smear negative and scanty samples, and can serve as a rapid diagnostic tool, particularly in isoniazid monoresistant cases of tuberculosis, which are not diagnosed by Xpert MTB/Rif.

Entities:  

Keywords:  Diagnostics; Drug resistance; Tuberculosis

Mesh:

Substances:

Year:  2016        PMID: 27499239      PMCID: PMC5072114          DOI: 10.1080/20477724.2016.1214350

Source DB:  PubMed          Journal:  Pathog Glob Health        ISSN: 2047-7724            Impact factor:   2.894


  14 in total

1.  Characterization of rpoB mutations in rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA sequencing and line probe assay.

Authors:  Cengiz Cavusoglu; Suleyha Hilmioglu; Sevinc Guneri; Altinay Bilgic
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

Review 2.  Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance.

Authors:  Stephen D Lawn; Mark P Nicol
Journal:  Future Microbiol       Date:  2011-09       Impact factor: 3.165

3.  First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as rifampin and isoniazid resistances.

Authors:  Valeriu Crudu; Ecaterina Stratan; Elena Romancenco; Vera Allerheiligen; Andreas Hillemann; Nicolae Moraru
Journal:  J Clin Microbiol       Date:  2012-02-01       Impact factor: 5.948

4.  Rifampin drug resistance tests for tuberculosis: challenging the gold standard.

Authors:  Armand Van Deun; Kya J M Aung; Valentin Bola; Rossin Lebeke; Mohamed Anwar Hossain; Willem Bram de Rijk; Leen Rigouts; Aysel Gumusboga; Gabriela Torrea; Bouke C de Jong
Journal:  J Clin Microbiol       Date:  2013-06-12       Impact factor: 5.948

5.  Comparison of Xpert MTB/RIF with line probe assay for detection of rifampin-monoresistant Mycobacterium tuberculosis.

Authors:  Syed Beenish Rufai; Parveen Kumar; Amit Singh; Suneel Prajapati; Veena Balooni; Sarman Singh
Journal:  J Clin Microbiol       Date:  2014-03-19       Impact factor: 5.948

6.  Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences.

Authors:  Francesc Coll; Ruth McNerney; Mark D Preston; José Afonso Guerra-Assunção; Andrew Warry; Grant Hill-Cawthorne; Kim Mallard; Mridul Nair; Anabela Miranda; Adriana Alves; João Perdigão; Miguel Viveiros; Isabel Portugal; Zahra Hasan; Rumina Hasan; Judith R Glynn; Nigel Martin; Arnab Pain; Taane G Clark
Journal:  Genome Med       Date:  2015-05-27       Impact factor: 11.117

7.  Characterization of multi-drug resistant Mycobacterium tuberculosis from immigrants residing in the USA using Ion Torrent full-gene sequencing.

Authors:  L T Daum; G W Fischer; J Sromek; M Khubbar; P Hunter; M S Gradus; S Bhattacharyya
Journal:  Epidemiol Infect       Date:  2013-09-27       Impact factor: 2.451

8.  Comparison of Xpert MTB/RIF Assay and GenoType MTBDRplus DNA Probes for Detection of Mutations Associated with Rifampicin Resistance in Mycobacterium tuberculosis.

Authors:  Arfatur Rahman; Mahfuza Sahrin; Sadia Afrin; Keith Earley; Shahriar Ahmed; S M Mazidur Rahman; Sayera Banu
Journal:  PLoS One       Date:  2016-04-07       Impact factor: 3.240

Review 9.  Extensively drug-resistant tuberculosis: epidemiology and management.

Authors:  Alberto Matteelli; Alberto Roggi; Anna Cc Carvalho
Journal:  Clin Epidemiol       Date:  2014-04-01       Impact factor: 4.790

10.  Multicenter Noninferiority Evaluation of Hain GenoType MTBDRplus Version 2 and Nipro NTM+MDRTB Line Probe Assays for Detection of Rifampin and Isoniazid Resistance.

Authors:  Ruvandhi R Nathavitharana; Doris Hillemann; Samuel G Schumacher; Birte Schlueter; Nazir Ismail; Shaheed Vally Omar; Welile Sikhondze; Joshua Havumaki; Eloise Valli; Catharina Boehme; Claudia M Denkinger
Journal:  J Clin Microbiol       Date:  2016-04-13       Impact factor: 5.948

View more
  7 in total

1.  Cascade of deoxyribozymes for the colorimetric analysis of drug resistance in Mycobacterium tuberculosis.

Authors:  Bidhan C Dhar; Adam J Reed; Suvra Mitra; Patricia Rodriguez Sanchez; Daria D Nedorezova; Ryan P Connelly; Kyle H Rohde; Yulia V Gerasimova
Journal:  Biosens Bioelectron       Date:  2020-06-13       Impact factor: 10.618

2.  Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2019-06-07

3.  Diagnostic utility of a line probe assay for multidrug resistant-TB in smear-negative pulmonary tuberculosis.

Authors:  Binit Kumar Singh; Surendra K Sharma; Rohini Sharma; Vishnubhatla Sreenivas; Vithal P Myneedu; Mikashmi Kohli; Dinkar Bhasin; Sanjay Sarin
Journal:  PLoS One       Date:  2017-08-22       Impact factor: 3.240

4.  Efficacy Of Line Probe Assay In Detection Of Drug-Resistant Pulmonary Tuberculosis In Comparison With GeneXpert And Phenotypic Methods In Iran And Genetic Analysis Of Isolates By MIRU-VNTR.

Authors:  Hossein Kazemian; Jalil Kardan-Yamchi; Abbas Bahador; Shadi Khonsari; Mahshid Nasehi; Gholamreza Hamzehloo; Farzam Vaziri; Mohammad Reza Salehi; Mohammad Mehdi Feizabadi
Journal:  Infect Drug Resist       Date:  2019-11-15       Impact factor: 4.003

5.  Accuracy of an amplicon-sequencing nanopore approach to identify variants in tuberculosis drug-resistance-associated genes.

Authors:  Carla Mariner-Llicer; Galo A Goig; Laura Zaragoza-Infante; Manuela Torres-Puente; Luis Villamayor; David Navarro; Rafael Borras; Álvaro Chiner-Oms; Iñaki Comas
Journal:  Microb Genom       Date:  2021-12

6.  Whole-Genome Sequencing to Identify Missed Rifampicin and Isoniazid Resistance Among Tuberculosis Isolates-Chennai, India, 2013-2016.

Authors:  Sembulingam Tamilzhalagan; Sivakumar Shanmugam; Ashok Selvaraj; Sakthi Suba; Chittibabu Suganthi; Patrick K Moonan; Diya Surie; Mukesh Kumar Sathyanarayanan; Narayanan Shivaram Gomathi; Lavanya Jayabal; Kuldeep Singh Sachdeva; Sriram Selvaraju; Soumya Swaminathan; Srikanth Prasad Tripathy; Patricia J Hall; Uma Devi Ranganathan
Journal:  Front Microbiol       Date:  2021-11-22       Impact factor: 5.640

7.  A Comparative Evaluation of the New Genexpert MTB/RIF Ultra and other Rapid Diagnostic Assays for Detecting Tuberculosis in Pulmonary and Extra Pulmonary Specimens.

Authors:  John Osei Sekyere; Nontobeko Maphalala; Lesibana A Malinga; Nontombi M Mbelle; Nontuthuko E Maningi
Journal:  Sci Rep       Date:  2019-11-12       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.